Novartis multiple sclerosis drug cuts relapses by a third in trials
⏮ BeforePatients relied on a standard treatment that still left relapse rates considerably higher.
✅ NowIn pivotal trials, the Novartis treatment cut relapse rates by a third.
In short
- The Novartis MS treatment cut relapse rates by a third against a standard treatment.
- The result comes from pivotal trials, the stage before regulatory review.
- Relapses are flare-ups of MS symptoms that can affect daily life.
Why the Good News Desk likes this one
Multiple sclerosis relapses can bring lasting disability, so a treatment that reduces them by a third matters to patients. The result is from pivotal trials, which are large studies run before a drug can be approved. Whether it reaches patients will depend on further review.
Advertisement
From STAT
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
Ask this story
More like this
Advertisement